
Sinusitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Sinusitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sinusitis – Drugs In Development, 2022, provides an overview of the Sinusitis (Ear Nose Throat Disorders) pipeline landscape.
Sinusitis is characterized by inflammation of the sinuses. This inflammation usually stems from infection caused by a viral or bacterial infection or by an allergy Symptoms include congestion and obstruction in the nose, pain, tenderness, hyposmia, halitosis, cough, toothache, headache and pain over the cheeks just below the eyes. Risk factors include asthma, nasal passage abnormality, immune system disorder, such as HIV/AIDS or cystic fibrosis and another allergic condition.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sinusitis – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Sinusitis (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Sinusitis (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 6, 7, 3, 14, 2 and 1 respectively.
Sinusitis (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sinusitis – Drugs In Development, 2022, provides an overview of the Sinusitis (Ear Nose Throat Disorders) pipeline landscape.
Sinusitis is characterized by inflammation of the sinuses. This inflammation usually stems from infection caused by a viral or bacterial infection or by an allergy Symptoms include congestion and obstruction in the nose, pain, tenderness, hyposmia, halitosis, cough, toothache, headache and pain over the cheeks just below the eyes. Risk factors include asthma, nasal passage abnormality, immune system disorder, such as HIV/AIDS or cystic fibrosis and another allergic condition.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sinusitis – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Sinusitis (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Sinusitis (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 6, 7, 3, 14, 2 and 1 respectively.
Sinusitis (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Sinusitis (Ear Nose Throat Disorders).
- The pipeline guide reviews pipeline therapeutics for Sinusitis (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sinusitis (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sinusitis (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sinusitis (Ear Nose Throat Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sinusitis (Ear Nose Throat Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sinusitis (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
109 Pages
- Introduction
- Global Markets Direct Report Coverage
- Sinusitis – Overview
- Sinusitis – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Sinusitis – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Sinusitis – Companies Involved in Therapeutics Development
- 3SBio Inc
- Amgen Inc
- Amytrx Therapeutics Inc
- AnaptysBio Inc
- Aodh Lifesciences Pvt Ltd
- Argenx SE
- Beijing FuKangren Bio-pharm Tech Co Ltd
- Biohaven Pharmaceutical Holding Company Ltd
- Furen Pharmaceutical Group Co Ltd
- GeneOne Life Science Inc
- Genrix (Shanghai) Biopharmaceutical Co Ltd
- GlycoMira Therapeutics Inc
- GSK plc
- Insmed Inc
- IVIEW Therapeutics Inc
- Jantar GmbH
- JiangSu Qyuns Therapeutics Co Ltd
- KeyMed Biosciences Inc
- Kyowa Kirin Co Ltd
- Lanier Biotherapeutics Inc
- Lyra Therapeutics Inc
- Maxwell Biosciences Inc
- Merck & Co Inc
- Nexeos Bio
- Nota Laboratories LLC
- OptiNose Inc
- Oticara Inc
- Pfizer Inc
- ProclaRx LLC
- Quorum Innovations LLC
- RAPT Therapeutics Inc
- Recce Pharmaceuticals Ltd
- Regeneron Pharmaceuticals Inc
- SaNOtize Research and Development Corp
- Shandong Boan Biotechnology Co Ltd
- Suzhou Connect Biopharmaceuticals Ltd
- Synermore Biologics Co Ltd
- Trellis Bioscience Inc
- Wuhan Yicheng Biotechnology Co Ltd
- Sinusitis – Drug Profiles
- (budesonide + povidone iodine) – Drug Profile
- 611 Anti-IL4R antibody – Drug Profile
- AMTX-100 – Drug Profile
- AOSI-04 – Drug Profile
- ARGX-118 – Drug Profile
- benralizumab – Drug Profile
- betamethasone dipropionate – Drug Profile
- brensocatib – Drug Profile
- CBP-201 – Drug Profile
- Chronic Sinusitis – Drug Profile
- CM-310 – Drug Profile
- CM-326 – Drug Profile
- depemokimab – Drug Profile
- dupilumab – Drug Profile
- etokimab – Drug Profile
- fluticasone propionate – Drug Profile
- GM-0111 – Drug Profile
- GM-1111 – Drug Profile
- GR-1802 – Drug Profile
- JT-1 – Drug Profile
- LNR-12538 – Drug Profile
- mepolizumab – Drug Profile
- mometasone furoate – Drug Profile
- mometasone furoate LA – Drug Profile
- Monoclonal Antibody to Antagonize IL-4 Receptor for Asthma, Sinusitis, Atopic Dermatitis and Food Allergies – Drug Profile
- NORS-4002 – Drug Profile
- NTXf-100 – Drug Profile
- omalizumab biosimilar – Drug Profile
- oxytetracycline hydrochloride – Drug Profile
- PCL-1550 – Drug Profile
- PF-06817024 – Drug Profile
- Qi-301 – Drug Profile
- quinine sulphate – Drug Profile
- QX-005N – Drug Profile
- RECCE-111 – Drug Profile
- rimegepant sulfate ODT – Drug Profile
- RPT-193 – Drug Profile
- Small Molecules for Rhinosinusitis – Drug Profile
- solithromycin – Drug Profile
- tebipenem pivoxil – Drug Profile
- tezepelumab – Drug Profile
- TRL-1068 – Drug Profile
- Yipiwutai – Drug Profile
- Sinusitis – Dormant Projects
- Sinusitis – Discontinued Products
- Sinusitis – Product Development Milestones
- Featured News & Press Releases
- May 01, 2022: Lyra Therapeutics presents positive data from LANTERN phase 2 study of LYR-210 for treatment of chronic rhinosinusitis at COSM 2022
- Apr 25, 2022: Lyra treats first subject in Phase II rhinosinusitis treatment trial
- Apr 25, 2022: Lyra Therapeutics announces first patient treated in phase 2 BEACON Clinical Trial of LYR-220 in post-surgical chronic rhinosinusitis patients
- Apr 21, 2022: Lyra Therapeutics announces two presentations at Upcoming COSM 2022
- Mar 28, 2022: Sanofi continues on path to industry leadership in Immunology with Dupixent (dupilumab) as key driver
- Mar 15, 2022: FDA declines approval for AstraZeneca’s chronic rhinosinusitis antibody
- Mar 07, 2022: Optinose reports positive top-line results in ReOpen1, a landmark Phase 3 Trial for XHANCE in chronic sinusitis
- Feb 28, 2022: Lyra Therapeutics announces first patient dosed in pivotal ENLIGHTEN I Clinical Trial of LYR-210 in chronic rhinosinusitis patients
- Feb 22, 2022: Biohaven enrolls first patient in phase 2/3 Sinusitis Trial of Nurtec ODT
- Feb 01, 2022: Positive Dupixent (dupilumab) data across five diseases with underlying type 2 inflammation to be presented at 2022 AAAAI Annual Meeting
- Jan 24, 2022: Lyra Therapeutics provides update on LYR-220 in surgically naive chronic rhinosinusitis patients
- Jan 24, 2022: Lyra Therapeutics provides update on LYR-210 in surgically naive chronic rhinosinusitis patients
- Nov 08, 2021: NUCALA (mepolizumab) the first and only anti-IL-5 add-on treatment approved in Canada that targets eosinophilic inflammation in adults with chronic rhinosinusitis with nasal polyps (CRSwNP)
- Oct 28, 2021: Optinose completes patient recruitment in second pivotal trial for XHANCE in chronic sinusitis
- Oct 04, 2021: Lyra Therapeutics presents new positive phase 2 LANTERN 6-month follow-up and LYR-210 pharmacokinetic data, and LANTERN manuscript wins award at the 67th Annual Meeting of the American Rhinologic Society
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Sinusitis, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Products under Development by Companies, 2022
- Table 5: Products under Development by Companies, 2022 (Contd..1)
- Table 6: Products under Development by Companies, 2022 (Contd..2)
- Table 7: Number of Products by Stage and Target, 2022
- Table 8: Number of Products by Stage and Mechanism of Action, 2022
- Table 9: Number of Products by Stage and Route of Administration, 2022
- Table 10: Number of Products by Stage and Molecule Type, 2022
- Table 11: Sinusitis – Pipeline by 3SBio Inc, 2022
- Table 12: Sinusitis – Pipeline by Amgen Inc, 2022
- Table 13: Sinusitis – Pipeline by Amytrx Therapeutics Inc, 2022
- Table 14: Sinusitis – Pipeline by AnaptysBio Inc, 2022
- Table 15: Sinusitis – Pipeline by Aodh Lifesciences Pvt Ltd, 2022
- Table 16: Sinusitis – Pipeline by Argenx SE, 2022
- Table 17: Sinusitis – Pipeline by Beijing FuKangren Bio-pharm Tech Co Ltd, 2022
- Table 18: Sinusitis – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022
- Table 19: Sinusitis – Pipeline by Furen Pharmaceutical Group Co Ltd, 2022
- Table 20: Sinusitis – Pipeline by GeneOne Life Science Inc, 2022
- Table 21: Sinusitis – Pipeline by Genrix (Shanghai) Biopharmaceutical Co Ltd, 2022
- Table 22: Sinusitis – Pipeline by GlycoMira Therapeutics Inc, 2022
- Table 23: Sinusitis – Pipeline by GSK plc, 2022
- Table 24: Sinusitis – Pipeline by Insmed Inc, 2022
- Table 25: Sinusitis – Pipeline by IVIEW Therapeutics Inc, 2022
- Table 26: Sinusitis – Pipeline by Jantar GmbH, 2022
- Table 27: Sinusitis – Pipeline by JiangSu Qyuns Therapeutics Co Ltd, 2022
- Table 28: Sinusitis – Pipeline by KeyMed Biosciences Inc, 2022
- Table 29: Sinusitis – Pipeline by Kyowa Kirin Co Ltd, 2022
- Table 30: Sinusitis – Pipeline by Lanier Biotherapeutics Inc, 2022
- Table 31: Sinusitis – Pipeline by Lyra Therapeutics Inc, 2022
- Table 32: Sinusitis – Pipeline by Maxwell Biosciences Inc, 2022
- Table 33: Sinusitis – Pipeline by Merck & Co Inc, 2022
- Table 34: Sinusitis – Pipeline by Nexeos Bio, 2022
- Table 35: Sinusitis – Pipeline by Nota Laboratories LLC, 2022
- Table 36: Sinusitis – Pipeline by OptiNose Inc, 2022
- Table 37: Sinusitis – Pipeline by Oticara Inc, 2022
- Table 38: Sinusitis – Pipeline by Pfizer Inc, 2022
- Table 39: Sinusitis – Pipeline by ProclaRx LLC, 2022
- Table 40: Sinusitis – Pipeline by Quorum Innovations LLC, 2022
- Table 41: Sinusitis – Pipeline by RAPT Therapeutics Inc, 2022
- Table 42: Sinusitis – Pipeline by Recce Pharmaceuticals Ltd, 2022
- Table 43: Sinusitis – Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Table 44: Sinusitis – Pipeline by SaNOtize Research and Development Corp, 2022
- Table 45: Sinusitis – Pipeline by Shandong Boan Biotechnology Co Ltd, 2022
- Table 46: Sinusitis – Pipeline by Suzhou Connect Biopharmaceuticals Ltd, 2022
- Table 47: Sinusitis – Pipeline by Synermore Biologics Co Ltd, 2022
- Table 48: Sinusitis – Pipeline by Trellis Bioscience Inc, 2022
- Table 49: Sinusitis – Pipeline by Wuhan Yicheng Biotechnology Co Ltd, 2022
- Table 50: Sinusitis – Dormant Projects, 2022
- Table 51: Sinusitis – Dormant Projects, 2022 (Contd..1)
- Table 52: Sinusitis – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Sinusitis, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products by Top 10 Targets, 2022
- Figure 4: Number of Products by Stage and Top 10 Targets, 2022
- Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Routes of Administration, 2022
- Figure 8: Number of Products by Stage and Routes of Administration, 2022
- Figure 9: Number of Products by Molecule Types, 2022
- Figure 10: Number of Products by Stage and Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.